Vertex Pharmaceuticals (BOVESPA:VRTX34) - Hisse Senedi Fiyatı, Haberler ve Analizler

VRTX34 Stoklara Genel Bakış

Bir biyoteknoloji şirketi olan Vertex Pharmaceuticals Incorporated, kistik fibrozis (KF) tedavisi için tedaviler geliştirmekte ve ticarileştirmektedir. Daha fazla detay

VRTX34 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 26.3% daha düşük bir oranda işlem görüyor

Kazançların yılda 47.38% oranında artması öngörülüyor

Risk Analizi

Risk kontrollerimizden VRTX34 için herhangi bir risk tespit edilmedi.

Vertex Pharmaceuticals Incorporated Rakipler

Blau Farmacêutica

BOVESPA:BLAU3

R$2.7b

Gilead Sciences

NasdaqGS:GILD

US$110.5b

CSL

ASX:CSL

AU$132.5b

Biomm

BOVESPA:BIOM3

R$1.2b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Vertex Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$655.56
52 Haftanın En Yüksek Seviyesi	US$748.45
52 Haftanın En Düşük Seviyesi	US$423.98
Beta	0.39
11 Aylık Değişim	-3.38%
3 Aylık Değişim	-1.17%
1 Yıllık Değişim	50.05%
33 Yıllık Değişim	152.32%
5 Yıllık Değişim	181.42%
Halka arzdan bu yana değişim	284.80%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	VRTX34	BR Biotechs	BR Pazar
7D	-7.4%	-5.5%	0.3%
1Y	50.1%	8.9%	-1.7%

Getiri vs. Endüstri: VRTX34 geçen yıl % 8.9 oranında getiri sağlayan BR Biotechs sektörünü aştı.

Getiri vs Piyasa: VRTX34 geçen yıl % -1.7 oranında getiri sağlayan BR Piyasasını aştı.

Fiyat Oynaklığı

Is VRTX34's price volatile compared to industry and market?
VRTX34 volatility
VRTX34 Average Weekly Movement	4.2%
Biotechs Industry Average Movement	9.1%
Market Average Movement	4.4%
10% most volatile stocks in BR Market	8.3%
10% least volatile stocks in BR Market	2.2%

İstikrarlı Hisse Senedi Fiyatı: VRTX34 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: VRTX34 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1989	5,400	Reshma Kewalramani	www.vrtx.com

Bir biyoteknoloji şirketi olan Vertex Pharmaceuticals Incorporated, kistik fibrozis (KF) tedavisi için tedaviler geliştirmekte ve ticarileştirmektedir. En az bir F508del mutasyonu olan 2 yaş ve üzeri KF hastaları için TRIKAFTA/KAFTRIO; 6 yaş ve üzeri KF hastaları için SYMDEKO/SYMKEVI; 1 yaş ve üzeri KF hastaları için ORKAMBI ve ivacaftor ile 1 yaş ve üzeri KF hastalarının tedavisi için KALYDECO'yu pazarlamaktadır. Şirketin boru hattı, Faz 1 klinik çalışmasında olan KF'nin altında yatan nedeni tedavi etmek için tasarlanmış bir CFTR mRNA terapötiği olan VX-522'yi; Faz 3 klinik çalışmasında olan akut ve nöropatik ağrı tedavisi için opioid olmayan bir ilaç olan VX-548'i; Faz 2/3 klinik çalışmasında olan orak hücre hastalığı ve transfüzyona bağlı beta talasemi tedavisi için Exa-cel'i içermektedir.

Vertex Pharmaceuticals Incorporated Temel Bilgiler Özeti

Vertex Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
VRTX34 temel i̇stati̇sti̇kler
Piyasa değeri	R$677.41b
Kazançlar(TTM)	-R$2.80b
Gelir(TTM)	R$61.94b

10.9x

P/S Oranı

-241.7x

F/K Oranı

VRTX34 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
VRTX34 gelir tablosu (TTM)
Gelir	US$10.63b
Gelir Maliyeti	US$4.93b
Brüt Kâr	US$5.69b
Diğer Giderler	US$6.17b
Kazançlar	-US$479.80m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.86
Brüt Marj	53.59%
Net Kâr Marjı	-4.52%
Borç/Özkaynak Oranı	0%

VRTX34 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

VRTX34 Stoklara Genel Bakış

Ödüller

Risk Analizi

Vertex Pharmaceuticals Incorporated Rakipler

BOVESPA:BLAU3

R$2.7b

NasdaqGS:GILD

US$110.5b

ASX:CSL

AU$132.5b

BOVESPA:BIOM3

R$1.2b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations

Vertex Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 01, 2024

Recent updates

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations

Vertex Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 01, 2024

Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director

Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024

Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis

Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024

Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024

Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi

Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director

Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older

Vertex Pharmaceuticals Incorporated Announces European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Announces United Kingdom Medicines and Healthcare Products Regulatory Agency Granted Conditional Marketing Authorization for CASGEVY

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With at Least One F508del Mutation

Vertex Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 06, 2023

Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors

Vertex Pharmaceuticals Incorporated Receives Chmp Positive Opinion for Kaftrio® (Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor for Children with Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

Vertex Pharmaceuticals Incorporated Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine

Vertex Pharmaceuticals Incorporated Announces European Commission Approval for ORKAMBI® (Lumacaftor/Ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 1 to <2 Years Old

Vertex Pharmaceuticals Incorporated Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $3,000 million worth of its shares.

Vertex Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 07, 2023

Vertex Pharmaceuticals Incorporated Announces to Present New Data on its Portfolio of Cystic Fibrosis Medicines at 2022 North American Cystic Fibrosis Conference

Vertex Pharmaceuticals Incorporated Revises Revenue Guidance for the Fiscal 2022

Vertex Pharmaceuticals Incorporated to Report Q3, 2022 Results on Oct 27, 2022

Vertex Pharmaceuticals Incorporated Advances Program Targeting Alpha-1 Antitrypsin Deficiency

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022

Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022

Vertex Announces U.S. FDA Approval for Orkambi® (Lumacaftor/Ivacaftor) in Children with Cystic Fibrosis Ages 12 to <24 Months

Vertex Pharmaceuticals Incorporated Reports Unaudited Intangible Asset Impairment Charge for the Three Months Ended June 30, 2022

Vertex Advances VX-548 in Acute and Neuropathic Pain

Vertex Pharmaceuticals Incorporated to Report Q2, 2022 Results on Aug 04, 2022

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million.

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million.

Vertex Announces FDA Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes

Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference

Vertex Pharmaceuticals Incorporated Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA

Vertex Pharmaceuticals Incorporated to Present New Data on VX-880 Clinical Trial